Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Cytogenetic polyclonality in hematologic malignancies

Johansson, Bertil LU ; Billström, Rolf ; Broberg Palmgren, Karin LU orcid ; Fioretos, Thoas LU ; Nilsson, Per-Gunnar LU ; Ahlgren, Tomas ; Malm, Claes ; Samuelsson, Bengt O and Mitelman, Felix LU orcid (1999) In Genes, Chromosomes and Cancer 24(3). p.222-229
Abstract
The present study was undertaken to ascertain the frequency of cytogenetic polyclonality in various hematologic malignancies and to investigate whether morphologic subgroup, age, gender, or previous genotoxic exposure influences the incidence. Among 2,243 cytogenetically investigated hematologic malignancies, 10 acute myeloid leukemias (AML), 5 myelodysplastic syndromes (MDS), 2 acute lymphoblastic leukemias (ALL), 1 acute undifferentiated leukemia (AUL), 1 atypical Philadelphia chromosome-negative (Ph-) chronic myeloid leukemia (CML), 1 chronic myeloproliferative disorder (CMD), and 1 chronic lymphoproliferative disorder (CLD) with karyotypically unrelated clones were identified, constituting 2.6% of AML, 1.6% of MDS, 0.8% of ALL, 13% of... (More)
The present study was undertaken to ascertain the frequency of cytogenetic polyclonality in various hematologic malignancies and to investigate whether morphologic subgroup, age, gender, or previous genotoxic exposure influences the incidence. Among 2,243 cytogenetically investigated hematologic malignancies, 10 acute myeloid leukemias (AML), 5 myelodysplastic syndromes (MDS), 2 acute lymphoblastic leukemias (ALL), 1 acute undifferentiated leukemia (AUL), 1 atypical Philadelphia chromosome-negative (Ph-) chronic myeloid leukemia (CML), 1 chronic myeloproliferative disorder (CMD), and 1 chronic lymphoproliferative disorder (CLD) with karyotypically unrelated clones were identified, constituting 2.6% of AML, 1.6% of MDS, 0.8% of ALL, 13% of AUL, 9.1% of Ph- CML, 1.5% of CMD, and 2.8% of CLD with chromosomal abnormalities. In contrast to the cytogenetic features, the X-inactivation pattern was monoclonal in the two informative female patients that could be investigated. Among 17,733 karyotypically aberrant published cases surveyed, significant frequency differences (P < 0.001) were discerned: 1.7% of 6,526 AML, 3.4% of 2,391 MDS, 0.4% of 1,920 Ph+ CML, 2.9% of 856 CMD, 0.9% of 4,226 ALL, and 5.8% of 1,814 CLD displayed unrelated clones. The incidence of cytogenetic polyclonality did not differ significantly among the MDS, CMD, or ALL subgroups, between males and females, between children (< 16 years) and adults, or between B- and T-cell ALL, whereas the frequencies varied among the AML FAB types (P < 0.05), among the different CLD entities (P < 0.001), and between B- and T-cell CLD (P < 0.001). Furthermore, the incidence was higher in therapy-related AML and MDS than in de novo AML and MDS (P < 0.001 and P < 0.01, respectively). (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Genes, Chromosomes and Cancer
volume
24
issue
3
pages
222 - 229
publisher
John Wiley & Sons Inc.
external identifiers
  • pmid:10451702
  • scopus:0032931871
ISSN
1045-2257
language
English
LU publication?
yes
id
75c3ac4d-8deb-4183-8f59-235cb0a0be15 (old id 1114302)
alternative location
http://www3.interscience.wiley.com/cgi-bin/fulltext/40004319/PDFSTART
date added to LUP
2016-04-01 12:08:42
date last changed
2022-01-26 23:25:17
@article{75c3ac4d-8deb-4183-8f59-235cb0a0be15,
  abstract     = {{The present study was undertaken to ascertain the frequency of cytogenetic polyclonality in various hematologic malignancies and to investigate whether morphologic subgroup, age, gender, or previous genotoxic exposure influences the incidence. Among 2,243 cytogenetically investigated hematologic malignancies, 10 acute myeloid leukemias (AML), 5 myelodysplastic syndromes (MDS), 2 acute lymphoblastic leukemias (ALL), 1 acute undifferentiated leukemia (AUL), 1 atypical Philadelphia chromosome-negative (Ph-) chronic myeloid leukemia (CML), 1 chronic myeloproliferative disorder (CMD), and 1 chronic lymphoproliferative disorder (CLD) with karyotypically unrelated clones were identified, constituting 2.6% of AML, 1.6% of MDS, 0.8% of ALL, 13% of AUL, 9.1% of Ph- CML, 1.5% of CMD, and 2.8% of CLD with chromosomal abnormalities. In contrast to the cytogenetic features, the X-inactivation pattern was monoclonal in the two informative female patients that could be investigated. Among 17,733 karyotypically aberrant published cases surveyed, significant frequency differences (P &lt; 0.001) were discerned: 1.7% of 6,526 AML, 3.4% of 2,391 MDS, 0.4% of 1,920 Ph+ CML, 2.9% of 856 CMD, 0.9% of 4,226 ALL, and 5.8% of 1,814 CLD displayed unrelated clones. The incidence of cytogenetic polyclonality did not differ significantly among the MDS, CMD, or ALL subgroups, between males and females, between children (&lt; 16 years) and adults, or between B- and T-cell ALL, whereas the frequencies varied among the AML FAB types (P &lt; 0.05), among the different CLD entities (P &lt; 0.001), and between B- and T-cell CLD (P &lt; 0.001). Furthermore, the incidence was higher in therapy-related AML and MDS than in de novo AML and MDS (P &lt; 0.001 and P &lt; 0.01, respectively).}},
  author       = {{Johansson, Bertil and Billström, Rolf and Broberg Palmgren, Karin and Fioretos, Thoas and Nilsson, Per-Gunnar and Ahlgren, Tomas and Malm, Claes and Samuelsson, Bengt O and Mitelman, Felix}},
  issn         = {{1045-2257}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{222--229}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{Genes, Chromosomes and Cancer}},
  title        = {{Cytogenetic polyclonality in hematologic malignancies}},
  url          = {{http://www3.interscience.wiley.com/cgi-bin/fulltext/40004319/PDFSTART}},
  volume       = {{24}},
  year         = {{1999}},
}